KY HB229 | 2024 | Regular Session
Status
Spectrum: Partisan Bill (Republican 6-0)
Status: Introduced on January 10 2024 - 25% progression, died in committee
Action: 2024-01-10 - to Committee on Committees (H)
Pending: House Committee On Committees Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 10 2024 - 25% progression, died in committee
Action: 2024-01-10 - to Committee on Committees (H)
Pending: House Committee On Committees Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Create a new section of KRS 217.005 to 217.215, the Kentucky Food, Drug, and Cosmetic Act, to define terms; require products that are known to be or could act as gene therapy to be labeled with the words "Potential Gene Therapy Product" or "Gene Therapy Product"; require any entity in the state that produces, sells, or distributes a product in this state with the capacity to infect an individual with a disease or to expose an individual with genetically modified material to provide information upon request on how individuals may be exposed; require informed consent before any entity makes available a product in this state that would act as a medical intervention, vaccine, drug, or genetic modification.
Title
AN ACT relating to gene therapy.
Sponsors
Rep. Emily Callaway [R] | Rep. Jennifer Henson Decker [R] | Rep. Danny Bentley [R] | Rep. John Hodgson [R] |
Rep. Marianne Proctor [R] | Rep. Steve Rawlings [R] |
History
Date | Chamber | Action |
---|---|---|
2024-01-10 | House | to Committee on Committees (H) |
2024-01-10 | House | introduced in House |
Subjects
Kentucky State Sources
Type | Source |
---|---|
Summary | https://apps.legislature.ky.gov/record/24RS/hb229.html |
Text | https://apps.legislature.ky.gov/recorddocuments/bill/24RS/hb229/orig_bill.pdf |